BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.

0.12
EUR
-0.01
(-4.69%)
-1.99EPS
6.01MMarket Cap
Nov 18Next Earn

Total Valuation

EUR

As of March 31, 2026, BioRestorative Therapies, Inc. carries a market capitalization of 6.01M, placing it among publicly traded companies globally. Its enterprise value stands at 2.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.01M
Enterprise Value2.91M

Important Dates

BioRestorative Therapies, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

Earnings Date11/18/2026

Share Statistics

As of March 31, 2026, BioRestorative Therapies, Inc. has 1.27M shares outstanding.

Shares Outstanding1.27M

Valuation Ratios

These figures are as of March 31, 2026. The price-to-sales ratio is 73.13, and the price-to-book ratio stands at 2.30.

PS Ratio73.13
PB Ratio2.30
P/TBV Ratio2.76
P/FCF Ratio-2.20
P/OCF Ratio-2.21

Enterprise Valuation

These figures are as of March 31, 2026. The EV/Sales ratio of 9.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.91M versus a market cap of 6.01M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales9.38

Financial Position

As of March 31, 2026, BioRestorative Therapies, Inc. maintains a current ratio of 2.35, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

Current Ratio2.35
Quick Ratio2.23

Financial Efficiency

EUR

Over the twelve months ended March 31, 2026, BioRestorative Therapies, Inc. posted a negative return on equity (ROE) of -241.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -147.75, reflecting losses generated across the asset base. The company generates approximately 24,767.47 in revenue per employee across its workforce of 12.50, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-241.50
Return on Assets (ROA)-147.75
Revenue Per Employee24,767.47
Employee Count12.50

Stock Price Statistics

EUR

As of the close on September 4, 2026, BioRestorative Therapies, Inc.'s stock has declined approximately 91.22% over the past 52 weeks. The 50-day moving average sits at 0.24, while the 200-day moving average is 0.44.

52-Week Price Change-91.22%
50-Day Moving Average0.24
200-Day Moving Average0.44

Income Statement

EUR

Over the twelve months ended March 31, 2026, BioRestorative Therapies, Inc. generated 309,593.34 in revenue and converted that into -9.57M in net income, yielding earnings per share of -1.99. EBITDA reached -12.12M, while operating income came in at -12.31M.

Revenue309,593.34
Gross Profit285,093.71
Operating Income-12.31M
Pretax Income-9.57M
Net Income-9.57M
EBITDA-12.12M
EBIT-12.31M
Earnings Per Share (EPS)-1.99

Balance Sheet

EUR

These figures are as of March 31, 2026. Total book value stands at 2.62M, with working capital of 1.89M providing operational flexibility.

Cash & Cash Equivalents3.11M
Net Debt-2.69M
Equity (Book Value)2.62M
Book Value Per Share2.05
Working Capital1.89M

Cash Flow

EUR

BioRestorative Therapies, Inc. produced -10.22M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -68,921.65 in capital expenditures, free cash flow totaled -10.29M - equivalent to -2.15 per share.

Operating Cash Flow-10.22M
Capital Expenditures-68,921.65
Free Cash Flow-10.29M
FCF Per Share-2.15

Margins

Over the twelve months ended March 31, 2026, BioRestorative Therapies, Inc. posted a gross margin of 92.09, reflecting its pricing power and cost economics. The operating margin of -3,975.00 and net profit margin of -3,089.55 provide insight into operational efficiency.

Gross Margin92.09
Operating Margin-3,975.00
Pretax Margin-3,089.55
Profit Margin-3,089.55
EBITDA Margin-3,916.15

Dividends & Yields

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -45.46: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -89.24, meaning BioRestorative Therapies, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-89.24
FCF Yield-45.46

Stock Splits

BioRestorative Therapies, Inc.'s most recent stock split took place on September 8, 2026 with a 20:1 split ratio.

Last Split Date9/8/2026
Split Ratio20:1

Scores

As of March 31, 2026, BioRestorative Therapies, Inc. has an Altman Z-Score of -66.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-66.42